No summary has been written for this.
Ascentage Pharma Group International is a clinical-stage biotechnology company focused on discovering, developing, and commercializing therapies for cancers, chronic hepatitis B virus, and age-related diseases. Its current portfolio centers on novel small-molecule drugs designed to regulate programmed cell death pathways, with emphasis on hematologic malignancies and other oncology indications. The company’s development pipeline includes product candidates such as olverembatinib, a BCR-ABL inhibitor, along with additional therapies targeting apoptosis-related pathways and other cancer-relevant mechanisms. Ascentage Pharma Group International operates as an integrated biopharmaceutical business, supporting research, clinical development, and commercialization activities across major markets including Mainland China and the United States. Headquartered in Suzhou, China, the company plays a specialized role in the global biotechnology sector by advancing targeted treatment options for diseases with significant unmet medical needs.
WebsiteSuzhou Industrial Park
Suzhou, 215000
China
The latest articles about AAPG.
Ascentage Pharma Group International has seen its share price move sharply in recent years, yet the current level still leaves a straightforward question for investors who care about fundamentals. Is the price you see on screen today reasonably aligned with what the business is generating in sales, or has sentiment moved further than the top line can comfortably support? With the stock down 56.4% over the past year, the slide puts fresh focus on whether the present valuation can still be...
William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
Investors talking about AAPG also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.